Valneva shares rose as investors reacted to five-year follow-up data from the IXCHIQ long-term study, which found that 94% of 221 healthy adults kept neutralizing antibody titers above the seroresponse threshold after a single dose of the chikungunya vaccine. The stock was trading at c2.652, up about 2.5% on the report.
The follow-up results, released early in the trading day, align with the companys expectations and add to a multi-year pattern of positive persistence readouts for IXCHIQ. Valneva emphasized that the findings extend the durability profile for the vaccine and provide additional evidence in support of its long-term immune response.
A notable aspect of the data set is the comparable antibody persistence observed in adults aged 65 and older relative to younger adults aged 18 to 64. Valneva reported similar geometric mean titers and seroresponse rates between these age groups - a material point for a vaccine aimed at a disease whose outbreaks can be geographically unpredictable.
Hanneke Schuitemaker, Valnevas Chief Scientific Officer, commented that the five-year data "further reinforce IXCHIQs unique value proposition." The company also said it will continue to follow participants for up to ten years to further characterize long-term immune durability, maintaining a runway of future data milestones.
Market reaction to the IXCHIQ durability readout built on momentum from the prior session, when Valneva shares jumped following positive Phase 2 results for the companys Shigella vaccine candidate S4V2. The Shigella program was highlighted as having no licensed competitor anywhere in the world, and that earlier announcement contributed to investor reassessment of Valnevas near-term narrative.
Broader market conditions provided a modestly supportive backdrop. The CAC 40 opened around 0.9% higher after a 1.2% gain on Monday, with the indexs advance aided by lower oil prices and a bounce in technology-related names. U.S. indices were broadly flat, which the company noted did not present a significant headwind to the move.
Analysts and market participants pointed to the combination of successive pipeline and commercial catalysts - the Phase 2 Shigella result followed by the IXCHIQ durability release - as the primary driver giving investors fresh incentives to re-evaluate Valnevas outlook. Even with the recent gains, the stock remains well below its 52-week high of c5.15, trading toward the upper end of its recent range.
Context and next steps
Valneva will continue long-term monitoring of IXCHIQ study participants through ten years, which keeps the vaccines data narrative active and creates additional potential catalysts. The companys recent string of clinical readouts has placed renewed focus on both its pipeline programs and potential commercial opportunities.
Bottom line
The five-year persistence data for IXCHIQ, combined with a positive Phase 2 Shigella result the prior session and supportive market conditions, underpinned Valnevas share gain. Continued follow-up through year ten ensures further data releases will remain part of the company's near-term story.